LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to
evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19
pneumonia. The primary objective of this study is to determine if enteral administration of
LB1148 will effect disease progression in hospitalized patients with moderate to severe
COVID-19 via measurement of the proportion of subjects alive and free of respiratory failure
at Day 28.